Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: I. Efficacy in Modifying Plasma Lipoproteins and Adverse Event Profile in 8245 Patients With Moderate Hypercholesterolemia

Archives of Internal Medicine

Volumn 151, Issue 1, 1991, Pages 43-49

  Bradford, Reagan H ^a   Shear, Charles L ^b   Chremos, Athanassios N ^b   Dujovne, Carlos ^c   Downton, Maria ^d   Franklin, Frank A ^e   Gould, A Lawrence ^b   Hesney, Michael ^b   Higgins, Jim ^d   Hurley, Dennis P ^d   Langendorfer, Alexandra ^b   Nash, David T ^f   Pool, James L ^g   Schnaper, Harold ^h  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d Clinical Research International Inc ^*  (United States)

^e LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; MEVINOLIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MYOPATHY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; LIVER FUNCTION TESTS; LOVASTATIN; MALE; MIDDLE AGE; MUSCULAR DISEASES; PATIENT COMPLIANCE; SUPPORT, NON-U.S. GOV'T; TRIGLYCERIDES;

EID: 0026088892     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1991.00400010067008     Document Type: Article

References (31)

1. Alberts AW, Chen J, Kuron G, Hunt V, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl—coenzyme A reductase and a cholesterol-agent. ProcNatlAcadSci U S A. 1980;77:3957-3961.
2. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin stimulates clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Trans Assoc Am Physicians. 1983;96:1-9.
3. Havel RJ, Hunninghake DB, Ilingworth DR, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Ann Intern Med. 1987;107:609-615.
4. The Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: a multicenter study. JAMA. 1986;256:2829-2834.
5. The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA. 1988;260:359-366.
6. The Lovastatin Study Group IV. A multicenter comparision of lovastatin and probucol in the therapy of severe primary hypercholesterolemia. Am J Cardiol. 1990;66:22B-30B.
7. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33.
8. Hoeg JM, Brewer HB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987;258:3532-3536.
9. Tobert JA. Efficacy Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J.
10. Laties AM, Keates EU, Taylor HR, et al. The human lens after 48 weeks of treatment with lovastatin. N Engl J Med. 1990;232:683-684. Letter.
11. Laties AM, Shear CL, Lippa EA, et al. The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results, II: assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol. In press.
12. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol, 1990;66:44B-55B.
13. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics. 1980;36:721-727.
14. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med. 1988;148:36-39.
15. Davidson CS, Leevy CM, Chamberlayne EC, eds. Guidelines for Detection of Hepatotoxicity due to Drugs and Chemicals. Washington, DC: National Institutes of Health; 1979:108-109. US Dept of Health, Education, and Welfare publication NIH 79-313.
16. Cutler SJ, Ederer F. Maximum utilization of the life-table method in analyzing survival. J Chronic Dis. 1958;8:699-712.
17. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
19. Harter HL. Order Statistics and Their Use in Testing Estimation. Washington, DC: Aerospace Research Laboratories, US Air Force; 1969:4, 240-241.
20. Mevacor (lovastatin, MSD). West Point, Pa: Merck Sharp & Dohme; July 1990. US package circular.
21. Knodel LC, Talbert RL. Adverse effects of hypolipidemic drugs. Med Toxicol. 1987;2:10-32.
22. MacDonald JS, Gerson RJ, Kornbrust DJ, et al. Preclinical evaluation of the potential toxicity of lovastatin. Am J Cardiol. 1988;62:16J-27J.
23. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71-75.
24. Schaefer EJ. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988;319:1222. Letter.
25. Black DM, Lamkin G, Olivera EH, Laskarzewski PM, Stein EA. Sleep disturbances and HMG-CoA reductase inhibitors. JAMA. 1990;264:1105. Letter.
26. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
27. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
28. Record NB Jr. Lovastatin vs cholestyramine therapy for primary hypercholesterolemia. JAMA. 1988;260:3590-3591. Letter.
29. Tikkanen MJ, Helve E, Jaattela A, et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. Am J Cardiol. 1988;62:35J-43J.
30. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. Am J Cardiol. 1990;65:23F-26F.
31. Alberts AW, McDonald GS, Till AE, Tobert JA. Lovastatin. Cardiovasc Drug Rev. 1989;7:88-109.